 |
Top 23 Leukemia and Blood Cancer treatment startups
Oct 24, 2025 | By Jason Kwon | 16 |
These startups develop new blood cancer treatments and diagnostics technologies, like bone marrow biopsy, targeted therapy, immunotherapy, stem cell transplantation, gene therapy...
1
Country: China | Funding: $504.7M
Ascentage Pharma is a China-based, global-oriented, clinical-stage biopharmaceutical company, dedicated to discovery and development of the “first-in-class” and the “best-in-class” targeted small-molecule cancer therapeutics.
Ascentage Pharma is a China-based, global-oriented, clinical-stage biopharmaceutical company, dedicated to discovery and development of the “first-in-class” and the “best-in-class” targeted small-molecule cancer therapeutics.
2
Country: USA | Funding: $3.4B
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
3
Country: USA | Funding: $1.2B
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
4
Country: Germany | Funding: $748.1M
MorphoSys' mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer.
MorphoSys' mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer.
5
Country: USA | Funding: $622M
Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.
Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.
6
Country: USA | Funding: $414.8M
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
7
Country: France | Funding: $393.5M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
8
Country: USA | Funding: $272.5M
Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development.
Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development.
9
Country: USA | Funding: $146.5M
Imago BioSciences is working on a treatment that shuts down an enzyme important to blood cancer growth.
Imago BioSciences is working on a treatment that shuts down an enzyme important to blood cancer growth.
10
Country: USA | Funding: $135.7M
Amphivena Therapeutics develops treatments to address hematologic malignancies.
Amphivena Therapeutics develops treatments to address hematologic malignancies.
11
Country: France | Funding: €101.6M
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
12
Country: China | Funding: $101.6M
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
13
Country: Switzerland | Funding: $65.7M
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
14
Country: Israel | Funding: $59M
BioSight is a biopharmaceutical company revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
BioSight is a biopharmaceutical company revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
15
Country: USA | Funding: $15M
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The first goal is to to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The first goal is to to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms.
16
Country: Poland | Funding: $3.25M
Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology.
Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology.
★
See also:
